TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin

References

• Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13(7):791–801.
   PubMed Web of Science ®Google Scholar
• Rucci N. Molecular biology of bone remodelling. Clin Cases Miner Bone Metab. 2008;5:49–56.
   PubMedGoogle Scholar
• Madel MB, Ibanez L, Wakkach A, et al. Immunefunction and diversity of osteoclasts in normal andpathological conditions. Front Immunol. 2019;10:1408.
   PubMed Web of Science ®Google Scholar
• Wu MY, Li CJ, Yiang GT, et al. Molecular regulation of bone metastasis pathogenesis. Cell Physiol Biochem. 2018;46(4):1423–1438.
   PubMedGoogle Scholar
• Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635–2643.
   PubMed Web of Science ®Google Scholar
• Kopper L, Kopper L. Denosumab-A powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts. Pathol Oncol Res. 2012;18(4):743–747.
   PubMed Web of Science ®Google Scholar
• Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537–549.
   PubMed Web of Science ®Google Scholar
• Behzatoglu K. Osteoclasts in tumor biology: metastasis and epithelial-mesenchymal-myeloid transition. Pathol Oncol Res. 2021;27:609472.
   Google Scholar
• Dembinski R, Prasath V, Bohnak C, et al. Estrogen receptor positive and progesterone receptor negative breast cancer: the role of hormone therapy. Horm Cancer. 2020;11(3–4):148–154.
   PubMed Web of Science ®Google Scholar
• Davis PJ, Mousa SA, Schechter GP, et al. Platelet ATP, thyroid hormone receptor on integrin αvβ3 and cancer metastasis. Horm Cancer. 2020;11(1):13–16.
   PubMed Web of Science ®Google Scholar
• Bolf EL, Gillis NE, Barnum MS, et al. The thyroid hormone receptor-RUNX2 axis: a novel tumor suppressive pathway in breast cancer. Horm Cancer. 2020;11(1):34–41.
   PubMed Web of Science ®Google Scholar
• Li R, Teng X, Zhu H, et al. MiR-4500 Regulates PLXNC1 and inhibits papillary thyroid cancer progression. Horm Cancer. 2019;10(4–6):150–160.
   PubMed Web of Science ®Google Scholar
• Mattiolo P, Fiadone G, Paolino G, et al. Epithelial-mesenchymal transition in undifferentiated carcinoma of the pancreas with and without osteoclast-like giant cells. Virchows Arch. 2021;478(2):319–326.
   PubMed Web of Science ®Google Scholar
• Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev. 2000;21(4):393–411.
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signalling in osteoblast and bone diseases. Gene. 2004;341:19–39.
   PubMed Web of Science ®Google Scholar
• Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635–2643.
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Armin HE, Heufelder AE, et al. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001;79(5–6):243–253.
   PubMed Web of Science ®Google Scholar
• Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–1268.
   PubMed Web of Science ®Google Scholar
• Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer. 2007;7(3):165–168.
   PubMed Web of Science ®Google Scholar
• Candi E, Agostini M, Melino G, et al. How the TP53 Family Proteins TP63 and TP73 Contribute to Tumorigenesis: regulators and Effectors. Off. J Hum Mutat. 2014;35(6):702–714.
   PubMed Web of Science ®Google Scholar
• Xu R, Garcia-Barros M, Wen S, et al. Tumor suppressor p53 links ceramide metabolism to DNA damage response through alkaline ceramidase 2. Cell Death Differ. 2018;25:841–856.
   PubMed Web of Science ®Google Scholar
• Agostini M, Niklison-Chirou MV, Annicchiarico-Petruzzelli MM, et al. p73 regulates primary cortical neuron metabolism: a global metabolic profile. Mol Neurobiol. 2018;55(4):3237–3250.
   PubMed Web of Science ®Google Scholar
• Amelio I, Antonov AA, Catani MV, et al. TAp73 promotes anabolism. Oncotarget. 2014;5(24):12820–12934.
   PubMedGoogle Scholar
• Viticchiè G, Agostini M, Lena AM, et al. p63 supports aerobic respiration through hexokinase II. Proc Natl Acad Sci USA [Internet]. 2015;112(37):11577–11582.
   PubMed Web of Science ®Google Scholar
• Bellomaria A, Barbato G, Melino G, et al. Recognition mechanism of p63 by the E3 ligase Itch: novel strategy in the study and inhibition of this interaction. Cell Cycle. 2012;11(19):3638–3648.
   PubMed Web of Science ®Google Scholar
• Bellomaria A, Barbato G, Melino G, et al. Recognition of p63 by the E3 ligase ITCH: effect of an ectodermal dysplasia mutant. Cell Cycle. 2010;9(18):3754–3763.
   Web of Science ®Google Scholar
• Chandar N, Swindle J, Szajkovics A, et al. Relationship of bone morphogenetic protein expression during osteoblast differentiation to wild type p53. J Orthop Res. 2005;23(6):1345–1353.
   PubMed Web of Science ®Google Scholar
• Wang X, Kua H-Y, Hu Y, et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol. 2006;172(1):115–125.
   PubMed Web of Science ®Google Scholar
• Velletri T, Huang Y, Wang Y, et al. Loss of p53 in mesenchymal stem cells promotes alteration of bone remodeling through negative regulation of osteoprotegerin. Cell Death Differ. 2021;28(1):156–169.
   PubMed Web of Science ®Google Scholar
• Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15(1):57–62.
   PubMed Web of Science ®Google Scholar
• Fowler AM, Salem K, DeGrave M, et al. Progesterone receptor gene variants in metastatic estrogen receptor positive breast cancer. Horm Cancer. 2020;11(2):63–75.
   PubMed Web of Science ®Google Scholar
• Cordo Russo RI, Chervo MF, Madera S, et al. Nuclear ErbB-2: a novel therapeutic target in ErbB-2-positive breast Cancer? Horm Cancer. 2019;10(2–3):64–70.
   PubMed Web of Science ®Google Scholar
• Bartha Á, Győrffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):2622.
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.
   Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404.
   PubMed Web of Science ®Google Scholar
• Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–4109.
   PubMed Web of Science ®Google Scholar
• Paul H, Reginato AJ, Schumacher HR. Alizarin Red S staininf asa a sceening test to detect calcium compounds in synovial fluid. Arthritis Rheum. 1983;26(2):191–200.
   PubMedGoogle Scholar
• Ghioni P, Bolognese F, Duijf PHG, et al. Complex transcriptional effects of p63 Isoforms: identification of Novel activation and repression domains. Mol Cell Biol. 2002;22(24):8659–8668.
   PubMed Web of Science ®Google Scholar
• Simonet W, Lacey D, Dunstan C, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–319.
   PubMed Web of Science ®Google Scholar
• Kong -Y-Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–323.
   PubMed Web of Science ®Google Scholar
• Sisay M, Mengistu G, Edessa D. The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. Onco Targets Ther. 2017;10:3801–3810.
   PubMed Web of Science ®Google Scholar
• Brown JM, Zhang J, Keller ET. Opg, RANKl, and RANK in cancer metastasis: expression and regulation. Cancer Treat Res. 2004;118:149–172.
   PubMedGoogle Scholar
• Tucci P, Agostini M, Grespi F, et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A. 2012;109(38):15312–15317.
   PubMed Web of Science ®Google Scholar
• Su X, Napoli M, Abbas HA, et al. TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway. Oncogene. 2017;36(17):2377–2393.
   PubMed Web of Science ®Google Scholar
• Chakrabarti R, Wei Y, Hwang J, et al. ΔNp63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol. 2014;16(10):1004–1015.
   PubMed Web of Science ®Google Scholar
• Memmi EM, Sanarico AG, Giacobbe A, et al. p63 sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc Natl Acad Sci. 2015;112(11):3499–3504.
   PubMed Web of Science ®Google Scholar
• Napoli M, Flores ER. The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy. Br J Cancer. 2017;116(2):149–155.
   PubMed Web of Science ®Google Scholar
• Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062–1078.
   PubMed Web of Science ®Google Scholar
• Nemajerova A, Amelio I, Gebel J, et al. Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism. Cell Death Differ. 2018;25(1):144–153.
   PubMed Web of Science ®Google Scholar
• Meletis K, Wirta V, Hede SM, et al. p53 suppresses the self-renewal of adult neural stem cells. Development. 2006;133(2):363–369.
   PubMed Web of Science ®Google Scholar
• Armesilla-Diaz A, Bragado P, Del Valle I, et al. p53 regulates the self-renewal and differentiation of neural precursors. Neuroscience. 2009;158(4):1378–1389.
   PubMed Web of Science ®Google Scholar
• Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404(6773):99–103.
   PubMed Web of Science ®Google Scholar
• Niklison-Chirou MV, Killick R, Knight RA, et al. How does p73 cause neuronal defects? Mol Neurobiol. 2016;53(7):4509–4520.
   PubMed Web of Science ®Google Scholar
• Agostini M, Tucci P, Chen H, et al. p73 regulates maintenance of neural stem cell. Biochem Biophys Res Commun. 2010;403(1):13–17.
   PubMed Web of Science ®Google Scholar
• Talos F, Abraham A, Vaseva AV, et al. p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis. Cell Death Differ. 2010;17(12):1816–1829.
   PubMed Web of Science ®Google Scholar
• Niklison-Chirou MV, Steinert JR, Agostini M, et al. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc Natl Acad Sci U S A. 2013;110(47):18952–18957.
   PubMed Web of Science ®Google Scholar
• Agostini M, Tucci P, Steinert JR, et al. microRNA-34a regulates neurite outgrowth, spinal morphology, and function. Proc Natl Acad Sci. 2011;108(52):21099–21104.
   PubMed Web of Science ®Google Scholar
• Agostini M, Tucci P, Killick R, et al. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci. 2011;108(52):21093–21098.
   PubMed Web of Science ®Google Scholar
• Amelio I, Bertolo R, Bove P, et al. Cancer predictive studies. Biol Direct. 2020;15(1):18.
   PubMed Web of Science ®Google Scholar
• Celli J, Duijf P, Hamel BCJ, et al. Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell. 1999;99(2):143–153.
   PubMed Web of Science ®Google Scholar
• Mills AA, Zheng B, Wang XJ, et al. P63 Is a P53 homologue required for limb and Epidermal Morphogenesis. Nature. 1999;398(6729):708–713.
   PubMed Web of Science ®Google Scholar
• Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398(6729):714–718.
   PubMed Web of Science ®Google Scholar
• Lena AM, Rossi V, Osterburg S, et al. The p63 C-terminus is essential for murine oocyte integrity. Nat Commun. 2021;12(1):383.
   PubMed Web of Science ®Google Scholar
• Infante M, Fabi A, Cognetti F, et al. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019;38(1):12.
   PubMed Web of Science ®Google Scholar
• Su X, Paris M, Gi YJ, et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell. 2009;5(1):64–75.
   PubMed Web of Science ®Google Scholar
• Desantis CE, Ma J, Ann SG, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–448.
   PubMed Web of Science ®Google Scholar
• WF A, Ha K, Ps R. Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst. 2011;103(18):1397–1402.
   PubMedGoogle Scholar
• Gatti V, Bongiorno-Borbone L, Fierro C, et al. p63 at the crossroads between stemness and metastasis in breast cancer. Int J Mol Sci. 2019;20(11):2683.
   PubMed Web of Science ®Google Scholar
• Amelio I, Bernassola F, Candi E. Emerging roles of long non-coding RNAs in breast cancer biology and management. Semin Cancer Biol. 2021;72:36–45.
   PubMed Web of Science ®Google Scholar
• Lung DK, Reese RM, Alarid ET. Intrinsic and extrinsic factors governing the transcriptional regulation of ESR1. Horm Cancer. 2020;11(3–4):129–147.
   PubMed Web of Science ®Google Scholar
• Sledge GW, Hortobagyi GN, Goodwin PJ, et al. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014;32(19):1979–1986.
   PubMed Web of Science ®Google Scholar
• Madera S, Chervo MF, Chiauzzi VA, et al. Nuclear PDCD4 expression defines a subset of luminal B-like breast cancers with good prognosis. Horm Cancer. 2020;11(5–6):218–239.
   PubMed Web of Science ®Google Scholar
• Pan Y, Wang X, Zhang Y, et al. Estradiol-Induced MMP-9 Expression via PELP1-mediated membrane-initiated signaling in ERα-positive breast cancer cells. Horm Cancer. 2020;11(2):87–96.
   PubMed Web of Science ®Google Scholar
• Smart E, Alejo LH, Frasor J. Cytoplasmic ERα and NFκB promote cell survival in mouse mammary cancer cell lines. Horm Cancer. 2020 Apr;11(2):76–86.
   PubMed Web of Science ®Google Scholar
• Lorona NC, Cook LS, Tang M-TC, et al. Recent use of oral contraceptives and risk of luminal B, triple-negative, and HER2-overexpressing breast cancer. Horm Cancer. 2019;10(2–3):71–76.
   PubMed Web of Science ®Google Scholar
• Santini D, Perrone G, Roato I, et al. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol. 2011;226(3):780–784.
   PubMed Web of Science ®Google Scholar
• Owen S, Ye L, Sanders AJ, et al. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res. 2013;33:199–206.
   PubMed Web of Science ®Google Scholar
• Holen I, Croucher PI, Hamdy FC, et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62:1619–1623.
   PubMed Web of Science ®Google Scholar
• Takayama K, Inoue T, Narita S, et al. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer. Cancer Lett. 2017;397:103–110.
   PubMed Web of Science ®Google Scholar
• Weichhaus M, Chung STM, Connelly L. Osteoprotegerin in breast cancer: beyond bone remodeling. Mol Cancer. 2015;14(1):117.
   PubMedGoogle Scholar
• Oktay K, Santaliz-Casiano A, Patel M, et al. A Computational statistics approach to evaluate blood biomarkers for breast cancer risk stratification. Horm Cancer. 2020;11(1):17–33.
   PubMed Web of Science ®Google Scholar